INTRODUCTION
Obesity and metabolic syndrome, commonly known as Syndrome X, have become increasingly common health concerns.1 As reported by the Centers for Disease Control and Prevention (CDC), nearly three-quarters of American adults are currently classified as obese or severely obese.2,3 Recently, glucagon-like peptide-1 (GLP-1) agonists, including semaglutide and tirzepatide, have gained popularity as a means of weight loss due to their effectiveness in controlling blood sugar and triggering satiety.4
The increasing use of GLP-1 agonists has raised concerns among physicians, non-physician providers, and patients regarding potential side effects. Skin-related issues, notably increased skin laxity and muscle loss, are often linked directly to these medications.5 However, attributing these skin changes exclusively to GLP-1 agonists might neglect other physiological factors associated with rapid weight loss. Several studies have documented that substantial weight loss, irrespective of the approach used, leads to noticeable changes in body composition, affecting fat stores, muscle health, and skin elasticity.6,7 Research comparing bariatric surgery, lifestyle interventions, and GLP-1 therapies consistently finds similar outcomes in tissue composition.8,9 These findings suggest that tissue changes are not solely a result of the medication itself but reflect a broader physiological response to rapid weight reduction, involving caloric restriction, hormonal shifts, and the pace at which fat and lean mass are lost.
This manuscript addresses the influence of rapid weight loss on body tissues, separating these general effects from those specifically caused by GLP-1 agonists. Recognizing substantial weight reduction as a major contributor to these changes can help dermatologists adopt comprehensive strategies for patient care. As GLP-1 agonists potentially gain approval for treating additional conditions such as alcoholism, obstructive sleep apnea, depression, and Alzheimer's disease, dermatologists will need to consider and manage a broader range of skin-related issues associated with these treatments.10
The increasing use of GLP-1 agonists has raised concerns among physicians, non-physician providers, and patients regarding potential side effects. Skin-related issues, notably increased skin laxity and muscle loss, are often linked directly to these medications.5 However, attributing these skin changes exclusively to GLP-1 agonists might neglect other physiological factors associated with rapid weight loss. Several studies have documented that substantial weight loss, irrespective of the approach used, leads to noticeable changes in body composition, affecting fat stores, muscle health, and skin elasticity.6,7 Research comparing bariatric surgery, lifestyle interventions, and GLP-1 therapies consistently finds similar outcomes in tissue composition.8,9 These findings suggest that tissue changes are not solely a result of the medication itself but reflect a broader physiological response to rapid weight reduction, involving caloric restriction, hormonal shifts, and the pace at which fat and lean mass are lost.
This manuscript addresses the influence of rapid weight loss on body tissues, separating these general effects from those specifically caused by GLP-1 agonists. Recognizing substantial weight reduction as a major contributor to these changes can help dermatologists adopt comprehensive strategies for patient care. As GLP-1 agonists potentially gain approval for treating additional conditions such as alcoholism, obstructive sleep apnea, depression, and Alzheimer's disease, dermatologists will need to consider and manage a broader range of skin-related issues associated with these treatments.10
MATERIALS AND METHODS
A narrative review was conducted to evaluate the dermatologic and structural consequences of rapid weight loss. Literature was identified through PubMed and Google Scholar searches for English-language articles published between 2000 and 2025. Keywords included "GLP-1 receptor agonists," "bariatric surgery," "skin laxity," "soft tissue changes," and "dermatologic management." Reference lists of key publications were manually screened to identify additional relevant studies.
